Fosun International Ltd Decreases Stake in IQVIA Holdings Inc. (NYSE:IQV)

Fosun International Ltd decreased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 21.6% during the 4th quarter, HoldingsChannel.com reports. The firm owned 2,000 shares of the medical research company’s stock after selling 550 shares during the quarter. Fosun International Ltd’s holdings in IQVIA were worth $463,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of IQV. Los Angeles Capital Management LLC lifted its holdings in IQVIA by 17.5% in the fourth quarter. Los Angeles Capital Management LLC now owns 118,616 shares of the medical research company’s stock worth $27,445,000 after acquiring an additional 17,677 shares during the last quarter. International Assets Investment Management LLC acquired a new position in shares of IQVIA during the fourth quarter valued at approximately $13,759,000. Schwartz Investment Counsel Inc. increased its stake in shares of IQVIA by 4.1% during the fourth quarter. Schwartz Investment Counsel Inc. now owns 178,690 shares of the medical research company’s stock valued at $41,345,000 after acquiring an additional 7,050 shares during the period. Gilliland Jeter Wealth Management LLC acquired a new position in shares of IQVIA during the fourth quarter valued at approximately $986,000. Finally, Dfpg Investments LLC acquired a new position in IQVIA in the fourth quarter worth approximately $1,106,000. Institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Truist Financial decreased their price objective on shares of IQVIA from $297.00 to $292.00 and set a “buy” rating for the company in a research note on Friday, May 3rd. Barclays lifted their target price on shares of IQVIA from $260.00 to $265.00 and gave the stock an “overweight” rating in a report on Thursday, February 15th. Evercore ISI cut their price objective on shares of IQVIA from $275.00 to $250.00 and set an “outperform” rating for the company in a research report on Friday, May 3rd. SVB Leerink assumed coverage on shares of IQVIA in a research note on Monday, February 26th. They issued an “outperform” rating and a $290.00 target price on the stock. Finally, StockNews.com raised shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Friday, February 16th. Three investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $257.57.

IQVIA Trading Up 0.5 %

Shares of NYSE:IQV traded up $1.20 during trading on Thursday, reaching $229.08. The stock had a trading volume of 54,439 shares, compared to its average volume of 954,569. The company has a debt-to-equity ratio of 2.02, a quick ratio of 0.88 and a current ratio of 0.88. IQVIA Holdings Inc. has a 52 week low of $167.42 and a 52 week high of $261.73. The firm’s fifty day moving average is $243.28 and its 200 day moving average is $225.03. The stock has a market cap of $41.74 billion, a price-to-earnings ratio of 31.13, a P/E/G ratio of 2.16 and a beta of 1.52.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, topping the consensus estimate of $2.82 by $0.02. The firm had revenue of $3.87 billion for the quarter, compared to the consensus estimate of $3.80 billion. IQVIA had a net margin of 9.01% and a return on equity of 29.17%. The business’s revenue was up 3.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.54 earnings per share. As a group, equities analysts forecast that IQVIA Holdings Inc. will post 10.12 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 1,000 shares of the stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $241.50, for a total value of $241,500.00. Following the sale, the insider now directly owns 20,836 shares of the company’s stock, valued at $5,031,894. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other IQVIA news, insider Ari Bousbib sold 31,678 shares of the firm’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the completion of the transaction, the insider now owns 796,752 shares of the company’s stock, valued at $199,610,278.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Eric Sherbet sold 1,000 shares of IQVIA stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $241.50, for a total value of $241,500.00. Following the completion of the transaction, the insider now directly owns 20,836 shares of the company’s stock, valued at approximately $5,031,894. The disclosure for this sale can be found here. Insiders sold 41,285 shares of company stock worth $10,331,003 over the last quarter. 1.60% of the stock is currently owned by company insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.